Posted by Michael Wonder on 08 Nov 2024
FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
8 November 2024 - Today, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus), a CD19 directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
Efficacy was evaluated in FELIX, an open-label, multi-centre, single-arm trial that enrolled adults with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia.
